NIH NIAID Clinical Trial Implementation Cooperative Agreement (U01)

This opportunity invites applications that propose implementation of investigator-initiated high-risk clinical trials. The trials must be hypothesis-driven, related to the research mission of the NIAID and considered a high priority by the Institute.

A high-risk clinical trial is defined by the NIAID as having one or more of the following attributes:

• provision of a non-routine intervention, that is, an intervention or non-routine use of an intervention that would not otherwise be provided for the condition under study in the local facility where the study is being conducted;
• administration of an unlicensed product; or
• administration of a licensed product for an unapproved indication.

Please see the link for more details:

http://grants.nih.gov/grants/guide/pa-files/PAR-11-234.html

The application due date is 13 September 2011.

Budgets are not limited, but must be realistic.

Defense Medical Research and Development Program - Military Infectious Diseases Clinical Trial Award

The Defense Health Program (Defense Medical Research and Development) has assigned funds to support clinical trials focused on combat-related infectious diseases. This Program Announcement/Funding Opportunity, DMRDP Military Infectious Diseases Clinical Trial Award (MID-CTA), is soliciting proposals focused on wound infection prevention and management as well as antimicrobial countermeasures. The FY12 MID-CTA seeks applications focused on reduction of morbidity and mortality of wound infections in wounded warriors and specifically seeks to accelerate transition of (1) medical technologies into deployed products and (2) advances in knowledge to improve clinical practices for use in the theater of war or in the clinical facilities of the Military Health System (MHS).

Proposed projects should be designed to demonstrate (1) the utility of a novel biomarker/assay, and/or (2) the safety and efficacy of novel therapies in human patients suffering from serious, debilitating wound infections due to trauma. The purpose of such demonstrations is to accelerate translation of greater medical capabilities to patients; this can range from proof of concept (i.e., first in human) trials through Phase II clinical trials, as well as Class I, II, or III medical device trials/testing.

Projects of interest are those focused on testing and translating investigational interventions/devices already proven in relevant definitive animal models, moving them into advanced clinical development.

Please see the link for more details
https://cdmrp.org/files/2012/dmrdp/midcta_pa.pdf

This grant opportunity is worth a maximum of 2,500,000 USD over 3 years


The application deadline is 7 September 2011.

NIH Promoting Engagement in Care and Timely Antiretroviral Initiation Following HIV Diagnosis (R01)

This program seeks research to improve medical care engagement and treatment adherence among HIV infected individuals in the first twelve months following HIV diagnosis, enrollment in HIV primary care, or initiation of antiretroviral treatment (ART). 


Please see the following link for more information:
http://grants.nih.gov/grants/guide/pa-files/PAS-10-148.html


Budgets are open and not limited, but must be realistic. The time period can be 1-5 years.

Research topics that are appropriate to this FOA include, but are not limited to:  

• Conduct formative research to develop and test interventions for rapidly and effectively linking individuals diagnosed with HIV to primary medical care, including but not limited to interventions that can be directly integrated within post-test HIV counseling, outreach efforts, peer-navigation programs, treatment for mental illness and substance abuse, and contingency management approaches.
• Evaluate policies and test interventions that seek to enhance enrollment in primary HIV medical care and reduce the time between HIV diagnosis and initial medical evaluation for recently diagnosed individuals, and/or time to achievement of first undetectable viral load among those for whom ART is indicated.
• Develop and test novel interventions focused on enhancing and maintaining patient retention in primary medical care, particularly within the first year following initiation of HIV care.
• Develop, refine, and validate systematic approaches toward assessing and improving patient readiness to initiate antiretroviral treatment that could be implemented in clinical practice in accordance with treatment guidelines and recommendations, such as measurement tools, placebo practice trials, or other approaches.
• Develop and test the impact of interventions designed to help patients make informed choices about voluntary ART initiation of antiretroviral medications, when clinically indicated.
• Develop and test highly feasible and low-cost clinic- or community-based interventions to improve patient adherence and persistence to antiretroviral medications in the period following ART initiation. Adherence intervention trials should assess impact on both behavioral adherence and biological outcomes such as viral suppression.
• Develop and test interventions to improve provider communication skills and messaging to patients (and patient-provider communication more generally) regarding ART initiation and early ART adherence and persistence.
• Assess organizational and systems-level factors or approaches that may impact linkage to HIV care, patient retention, antiretroviral initiation, or antiretroviral adherence to inform policy and clinic practice.
• Develop and test targeted interventions designed to reduce documented racial/ethnic, gender, and age-related disparities in HIV care engagement and treatment outcomes.

The application deadline is 9 September 2011.

Gates Foundation: Open Letters of Inquiry

The Gates Foundation regularly accepts Letters of Inquiry (LOI) that propose projects that investigate malaria, nutrition, and/or neglected diseases. Some of the things they will consider:

• Improve diagnostics so that diseases can be detected early.
• Develop vaccines and drug treatments that are safe, effective, and affordable.
• Control the source of the disease.
• Attempt to eliminate or eradicate some diseases entirely.
• Advocate for public support to address these neglected diseases.

Please see the following link for more details:

http://www.gatesfoundation.org/grantseeker/Pages/grant-opportunities.aspx

Grant budgets are open-ended (but must be reasonable) and there is no specific deadline.

NIH Strategies for the Protection of Pregnant Women and Infants Against Infectious Diseases (R01)

This grant opportunity proposes that infectious diseases are studied in pregnant women, infants, and unborn fetuses.  

This grant is worth $350,000 per year for up to 5 years.

Studies looking at any infectious disease (except HIV/AIDS) are welcome, although some diseases of specific interest are: human cytomegalovirus (HCMV), adenoviruses, human papillomaviruses (HPV), Toxoplasma gondii, and falciparum malaria.

Applicants should propose hypothesis-driven specific aims that directly address one or more of the three major areas below.

• Mechanisms of pathogen-mediated placental pathology and/or dysfunction.
• Mechanisms of trans-placental transmission of pathogens and their components.
• Mechanisms of pathogen-mediated pregnancy loss and pre-term delivery.

Applicants are highly encouraged to use, where appropriate, an approach that incorporates human subjects and human tissues.

Please see the following link for more information: 

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-11-036.html

The deadline is 13 October 2011

NIH Therapeutics for Neurotropic Biodefense Toxins and Pathogens (R21/R33)

This NIH grants seeks studies addressing pathogens such as rabies and Japanese encephalitis virus in the following focus areas:

• development of improved neurotropic therapeutic delivery technologies;
• development or optimization of candidate therapeutic delivery platforms;
• identification and validation of new therapeutic targets such as receptors that enable toxins or pathogens to cross the blood-brain barrier or enter neurons;
• research utilizing genomics, proteomics, metabolomics, and/or bioinformatics to identify therapeutic targets;
• screening and identification of new therapeutic agents directed against neurotropic toxins or pathogens;
• preclinical efficacy and/or toxicity testing of candidate therapeutics; and lead candidate optimization.

Responsive applications must address discovery and/or development of new therapeutics against one or more of the following neurotropic agents.

This grant is worth $275,000 over the first two years, and then $300,000 per year for three additional years.

Please see the following link for more information:
http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-11-027.html


The deadline is 24 October 2011

Introduction

This blog is facilitated by the Office of Research Services at the Mahidol University Faculty of Tropical Medicine. We will constantly update you on funding opportunities we believe TropMed staff are eligible for, as well as remind you of deadlines, and other news. Please subscribe by submitting you email address under the "Follow by email" heading, and you can receive updates through your email address.